REGN:NASDAQ

Regeneron trades at $781.6, just above its 20‑day SMA of $779.8 and comfortably within a bullish trend direction, while the 14‑day RSI sits at a neutral 52.2. The MACD histogram is negative (‑2.04) indicating short‑term bearish momentum, but price remains above the key support level of $745.1 and below the resistance at $815, suggesting a relatively tight trading range. Valuation metrics show a forward P/E of 14.8 versus an industry average of 25.4, and a dividend yield of 0.49% with a modest payout ratio of 8.5%, underscoring a sustainable dividend. The stock’s beta of 0.65 points to lower market sensitivity, yet 30‑day volatility is high at ~30%, reflecting biotech‑specific price swings. Fundamentally, REGN posted $14.34 B in revenue with 2.5% YoY growth, strong margins (gross 44.6%, operating 23.1%, profit 31.4%), and robust cash generation ($8.6 B cash, $3.26 B free cash flow). Recent Phase 3 initiation of olatorepatide for weight‑loss and an analyst consensus “Buy” with a median target of $875 provide upside potential of roughly 11.6%. However, the DCF fair value of $528.3 suggests the market may be pricing in premium expectations, flagging a valuation gap.